Ultragenyx RARE NASDAQ · Healthcare · United States
$16.27 -2.57% -$0.43
Summary
48 / 100 · Bulios Score
What speaks for it
- Revenue grew by 23% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- It missed profit estimates 6 times in the last 8 quarters.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it grew by 23% a year. For the next fiscal year analysts expect revenue to grow by 12%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $524.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 21
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $25.46 is 56% above today's price. 62% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 55%
- Royalty 45%
By region
- North America 56%
- Latin America 25%
- EMEA 16%
- Asia Pacific 2.7%
Product brings in 55% of revenue.
Segments in detail